Recent review demonstrates improved bioavailability and therapeutic potential of curcumin analogues, highlighting antioxidant and anti‐inflammatory effects.
Curcumin, a principal component of the Indian spice turmeric, exhibits a wide range of biological activities but suffers from poor pharmacokinetic and pharmacodynamic profiles. To overcome these limitations, monocarbonyl analogues of curcumin (MACs) have been developed through structural modifications, resulting in improved bioavailability and enhanced therapeutic potential. This review highlights recent advances in the development of MACs with a focus on their antioxidant, anti‐inflammatory, antitubercular, antimicrobial, antidiabetic, antileishmanial, and anti‐Alzheimer properties. Moreover, insights into their structure–activity relationships (SAR) are also discussed.
No takes yet. Share an insight, caveat, or question.
Panchgalle et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: